ATRX (Adhera Therapeutics) Shiller PE Ratio: (As of Sep. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATRX Adhera Therapeutics Inc ATRX
12 GF Score
Price $0.00
View Full Analysis

What is Adhera Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Adhera Therapeutics  (OTCPK:ATRX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Adhera Therapeutics Shiller PE Ratio Related Terms


Adhera Therapeutics Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Adhera Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adhera Therapeutics Shiller PE Ratio Chart

Adhera Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Adhera Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ATRX vs PKBO, ARDS, NYMXF: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Adhera Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adhera Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adhera Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Adhera Therapeutics's Shiller PE Ratio falls into.


ATRX
12GF Score
Adhera Therapeutics Inc ATRX
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adhera Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Adhera Therapeutics's E10 for the quarter that ended in Sep. 2023 is calculated as:

For example, Adhera Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.8278/307.7890*307.7890
=-0.828

Current CPI (Sep. 2023) = 307.7890.

Adhera Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201309 -12.000 234.149 -15.774
201312 -23.190 233.049 -30.627
201403 -140.000 236.293 -182.360
201406 22.000 238.343 28.410
201409 -56.000 238.031 -72.412
201412 92.488 234.812 121.232
201503 -8.000 236.119 -10.428
201506 -6.000 238.638 -7.739
201509 -12.000 237.945 -15.522
201512 -4.000 236.525 -5.205
201603 -0.586 238.132 -0.757
201606 -0.600 241.018 -0.766
201609 -4.000 241.428 -5.099
201703 -2.000 243.801 -2.525
201706 -2.400 244.955 -3.016
201709 -2.000 246.819 -2.494
201712 -5.690 246.524 -7.104
201803 -2.587 249.554 -3.191
201806 -9.091 251.989 -11.105
201809 -14.514 252.439 -17.696
201812 -7.490 251.233 -9.176
201903 -5.464 254.202 -6.615
201906 -5.777 256.143 -6.942
201909 -5.419 256.759 -6.496
201912 -8.201 256.974 -9.823
202003 -4.087 258.115 -4.873
202006 -2.370 257.797 -2.830
202009 -1.706 260.280 -2.017
202012 -1.595 260.474 -1.884
202103 -2.342 264.877 -2.721
202106 -1.553 271.696 -1.759
202109 -6.384 274.310 -7.163
202112 -2.405 278.802 -2.655
202203 -0.510 287.504 -0.546
202206 -0.269 296.311 -0.280
202209 -11.465 296.808 -11.889
202212 -0.121 296.797 -0.125
202303 -0.287 301.836 -0.293
202306 -0.014 305.109 -0.014
202309 -0.828 307.789 -0.828

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Adhera Therapeutics Business Description

Address 8000 Innovation Parkway, Baton Rouge, LA, USA, 70820
Adhera Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing advanced drug candidates through accelerated pathways. The company's pipeline includes MLR-1019 for Parkinson's disease and MLR-1023 for diabetes, both licensed from the Melior Discovery group. MLR-1019 (armesocarb) is a drug candidate targeting both movement and non-movement symptoms of Parkinson's disease, while MLR-1023 (tolimidone) is being developed for Type 1 diabetes and has undergone Phase 2a and 2b studies in Type 2 diabetes patients. It also explores additional drug development opportunities and maintains legacy assets such as CEQ508, an oral RNA therapy candidate for polyps associated with Familial Adenomatous Polyposis (FAP).
12GF Score

Get the complete analysis for ATRX

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price